Kobayashi Pharmaceutical Co., Ltd.
Stock Price Chart
2026/06/15 UpdatedPrice Trend
2026/06/15 UpdatedPrice & Trading Details
2026/06/15 UpdatedPRICE
TRADING
Analyst Recommendations 7 analysts
Updated 2026/06/05Earnings Calendar
Updated 2026/06/05Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/05/07 | ¥5.38 | ¥13.95 | +159.3% |
| 2026/02/09 | ¥81.80 | ¥-42.41 | -151.9% |
| 2025/11/10 | ¥43.93 | ¥48.99 | +11.5% |
| 2025/08/04 | ¥24.03 | ¥20.75 | -13.6% |
Shareholder Composition
Updated 2026/06/05Major Holders
Updated 2026/06/05| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
735.8K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
475.4K | +2.77% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
351.8K | 0.00% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
184.8K | -0.22% | |
|
SCHWAB STRATEGIC TRUST-Schwab International Equity ETF
|
118.8K | +0.93% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Index Fd.
|
110.1K | 0.00% |
Dividend History 4Years Growth
Updated 2026/06/14| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥104 | +2.0% |
| 2024 | ¥102 | +1.0% |
| 2023 | ¥101 | +12.2% |
| 2022 | ¥90 | +8.4% |
| 2021 | ¥83 | - |
Financial Performance
2026/06/14 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥155,252M | ¥166,258M | ¥173,455M | ¥165,600M |
| Gross Profit | ¥88,773M | ¥92,331M | ¥96,375M | ¥87,603M |
| Operating Income | ¥26,071M | ¥26,674M | ¥25,784M | ¥24,869M |
| Pretax Income | ¥27,654M | ¥27,968M | ¥27,588M | ¥13,942M |
| Net Income | ¥19,715M | ¥20,022M | ¥20,338M | ¥10,067M |
| EPS | ¥252.36 | ¥259.59 | ¥268.16 | ¥135.42 |
| Operating Margin | 16.79% | 16.04% | 14.86% | 15.02% |
| Balance Sheet | ||||
| Total Assets | ¥252,554M | ¥255,827M | ¥267,473M | ¥265,368M |
| Total Equity | ¥195,599M | ¥197,899M | ¥204,816M | ¥213,466M |
| Total Liabilities | ¥56,955M | ¥57,928M | ¥62,657M | ¥51,902M |
| Cash | ¥95,024M | ¥96,233M | ¥71,536M | ¥50,873M |
| Interest-bearing Debt | ¥630M | ¥792M | ¥987M | ¥846M |
| Equity Ratio | 77.45% | 77.36% | 76.57% | 80.44% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥22,419M | ¥31,914M | ¥18,360M | ¥11,246M |
| Investing CF | ¥7,991M | -¥14,312M | -¥19,576M | -¥18,415M |
| Financing CF | -¥10,377M | -¥20,759M | -¥19,463M | -¥7,768M |
| Free CF | ¥18,234M | ¥15,685M | ¥4,791M | -¥15,383M |
| Efficiency | ||||
| ROE | 10.08% | 10.12% | 9.93% | 4.72% |
| ROA | 7.81% | 7.83% | 7.60% | 3.79% |
Latest IR Information
-
[Kobayashi Pharmaceutical] Q1 2026 Earnings Results | Sales of ¥33.6 billion (+3.2%)
Kobayashi Pharmaceutical's Q1 2026 recorded sales of ¥33.6 billion (YoY +3.2%), with net profit decreasing to approximately ¥1.0 billion. Healthcare and daily用品 are showing signs of recovery, but profits have declined. Continued attention to business performance is warranted.
Read more -
Approach and Policy Regarding the Reduction of Investment Unit
Kobayashi Pharmaceutical Co., Ltd. recognizes that reducing the investment unit is an effective measure to expand the investor base and revitalize the stock market, and has indicated a policy to consider this appropriately based on future market trends.
Read more -
Receipt of Partial Withdrawal of Shareholder Proposal and Agenda Items for the 108th Annual General Meeting of Shareholders
At the 108th Annual General Meeting of Shareholders scheduled for March 27, 2026, the shareholder proposal to elect one auditor was withdrawn, and the Company’s Board of Directors consented to this withdrawal.
Read more -
Notice Concerning Dividend of Surplus and Withdrawal of Special Reserves
The year-end dividend for the fiscal year ending December 2025 is 60 yen per share, with a total dividend amount of 4,460 million yen. A transfer of 8,300 million yen from special reserves to retained earnings will be made, effective...
Read more -
Notice Regarding Partial Amendment of Articles of Incorporation Due to Transition to a Company with an Audit and Supervisory Committee
Kobayashi Pharmaceutical Co., Ltd. plans to propose amendments to its articles of incorporation at the 108th Annual General Meeting of Shareholders scheduled for March 27, 2026, to transition to a company with an audit and supervisory committee, aiming to strengthen...
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥5,523
Rating Score: 3.00 (Based on 7 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, paper products, and hand warmers; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, sales promotion and market research, promotional goods production and sales, and asset management activities, as well as in pharmacy, retail, and cleaning industries. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.
